Medite Cancer Diagnostics Inc MDIT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Oct 15, 2018 (filed on Oct 19, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

80,000

Price:

$0.08
Oct 15, 2018 (filed on Oct 19, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,973,333

Price:

$0.08
Jul 27, 2018 (filed on Jul 30, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

133,333

Price:

$0.08
Jul 25, 2018 (filed on Jul 30, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,100,000

Price:

$0.08
Jul 20, 2018 (filed on Jul 20, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

6,933,333

Price:

$0.08
Jul 03, 2018 (filed on Jul 10, 2018)

Insider Name:

Abeles John H

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jun 28, 2018 (filed on Jul 05, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,333,334

Price:

$0.08
May 08, 2018 (filed on May 08, 2018)

Insider Name:

Fortunoff Gregory

Ownership Type:

Direct Ownership

Securities:

Warrant

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

Filings by filing date

Oct 15, 2018 (filed on Oct 19, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

80,000

Price:

$0.08
Oct 15, 2018 (filed on Oct 19, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,973,333

Price:

$0.08
Jul 25, 2018 (filed on Jul 30, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,100,000

Price:

$0.08
Jul 27, 2018 (filed on Jul 30, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

133,333

Price:

$0.08
Jul 20, 2018 (filed on Jul 20, 2018)

Insider Name:

Von Rump Stephen L.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jul 09, 2018 (filed on Jul 12, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

6,933,333

Price:

$0.08
Jul 03, 2018 (filed on Jul 10, 2018)

Insider Name:

Abeles John H

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

400,000

Price:

$0.08
Jun 28, 2018 (filed on Jul 05, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,333,334

Price:

$0.08
Apr 26, 2018 (filed on Jul 05, 2018)

Insider Name:

Lewis William Austin IV

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,000,000

Price:

$0.08

News

Biz Brief

Sector: Healthcare	Industry: Advanced Medical Equipment & Technology

See Regulatory Filings on SEC

Company Contact

Address:	414 N Orleans St Ste 502 CHICAGO IL 60654-4498
Tel:	N/A
Website:	https://www.medite-group.com
IR:	See website

Key People

W. Austin Lewis Chairman of the Board	Stephen L. Von Rump President, Chief Executive Officer, Director	Gary D. Pickett Chief Financial Officer
Michaela Ott Chief Operating Officer	Jeff Rencher Chief Marketing and Business Development Officer

Business Overview

MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers.

Financial Overview

For the six months ended 30 June 2018, Medite Cancer Diagnostics Inc revenues increased 19% to $3.8M. Net loss applicable to common stockholders decreased 23% to $2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling decrease of 16% to $1.7M (expense), Research and development, decrease of 25% to $563K (expense).

Employees:	5 as of Mar 27, 2014

Reporting Currency:	U.S. Dollars
Enterprise value:	$21.06M as of Jun 30, 2018
Annual revenue (TTM):	$7.43M as of Jun 30, 2018
EBITDA (TTM):	-$5.00M as of Jun 30, 2018
Net annual income (TTM):	-$6.29M as of Jun 30, 2018
Free cash flow (TTM):	-$4.94M as of Jun 30, 2018
Net Debt Last Fiscal Year:	$5.40M as of Jun 30, 2018
Shares outstanding:	73,506,201 as of Aug 10, 2018
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization